ImmunityBio Says Steps Taken to Address FDA Concerns Over Anktiva Podcast, TV Ad

MT Newswires Live04-06

ImmunityBio (IBRX) said Monday that it has removed a podcast about its bladder cancer drug Anktiva from its website and asked third-party hosting platforms to remove the podcast to address the US Food and Drug Administration's concerns.

The company also said the television ad questioned by the regulator never aired.

In addition, ImmunityBio said it is executing other measures to improve advertising compliance, including expanded promotional review protocols and mandatory executive training.

In March, the FDA issued a warning letter to the company citing "false or misleading" promotional materials for Anktiva.

Anktiva, or nogapendekin alfa inbakicept-pmln), is indicated in combination with Bacillus Calmette-Guerin for the treatment of adults with BCG-unresponsive nonmuscle invasive bladder cancer with carcinoma in situ with or without papillary tumors, the regulator said.

Shares of ImmunityBio were up 1.2% pre-bell Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2625679011?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-06 20:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625679011","market":"nz","top_or_hot":-1,"title":"ImmunityBio Says Steps Taken to Address FDA Concerns Over Anktiva Podcast, TV Ad","media":"MT Newswires Live","content":"<html><body><p> ImmunityBio (IBRX) said Monday that it has removed a podcast about its bladder cancer drug Anktiva from its website and asked third-party hosting platforms to remove the podcast to address the US Food and Drug Administration's concerns.</p><p>The company also said the television ad questioned by the regulator never aired.</p><p>In addition, ImmunityBio said it is executing other measures to improve advertising compliance, including expanded promotional review protocols and mandatory executive training.</p><p>In March, the FDA issued a warning letter to the company citing \"false or misleading\" promotional materials for Anktiva.</p><p>Anktiva, or nogapendekin alfa inbakicept-pmln), is indicated in combination with Bacillus Calmette-Guerin for the treatment of adults with BCG-unresponsive nonmuscle invasive bladder cancer with carcinoma in situ with or without papillary tumors, the regulator said.</p><p>Shares of ImmunityBio were up 1.2% pre-bell Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunityBio Says Steps Taken to Address FDA Concerns Over Anktiva Podcast, TV Ad</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunityBio Says Steps Taken to Address FDA Concerns Over Anktiva Podcast, TV Ad\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-06 20:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> ImmunityBio (IBRX) said Monday that it has removed a podcast about its bladder cancer drug Anktiva from its website and asked third-party hosting platforms to remove the podcast to address the US Food and Drug Administration's concerns.</p><p>The company also said the television ad questioned by the regulator never aired.</p><p>In addition, ImmunityBio said it is executing other measures to improve advertising compliance, including expanded promotional review protocols and mandatory executive training.</p><p>In March, the FDA issued a warning letter to the company citing \"false or misleading\" promotional materials for Anktiva.</p><p>Anktiva, or nogapendekin alfa inbakicept-pmln), is indicated in combination with Bacillus Calmette-Guerin for the treatment of adults with BCG-unresponsive nonmuscle invasive bladder cancer with carcinoma in situ with or without papillary tumors, the regulator said.</p><p>Shares of ImmunityBio were up 1.2% pre-bell Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LABU","symbol_name":"三倍做多标普生物-Direxion","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2625679011","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2625679011","pubTimestamp":1775478467,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"ImmunityBio  said Monday that it has removed a podcast about its bladder cancer drug Anktiva from its website and asked third-party hosting platforms to remove the podcast to address the US Food and Drug Administration's concerns.The company also said the television ad questioned by the regulator never aired.In addition, ImmunityBio said it is executing other measures to improve advertising compliance, including expanded promotional review protocols and mandatory executive training.In March, the FDA issued a warning letter to the company citing \"false or misleading\" promotional materials for Anktiva.Anktiva, or nogapendekin alfa inbakicept-pmln), is indicated in combination with Bacillus Calmette-Guerin for the treatment of adults with BCG-unresponsive nonmuscle invasive bladder cancer with carcinoma in situ with or without papillary tumors, the regulator said.Shares of ImmunityBio were up 1.2% pre-bell Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"LABU":"三倍做多标普生物-Direxion","TV":"墨西哥电视"},"translate_title":"ImmunityBio表示已采取措施解决FDA对Anktiva播客和电视广告的担忧","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"TV":1.5},"content_text":"ImmunityBio (IBRX) said Monday that it has removed a podcast about its bladder cancer drug Anktiva from its website and asked third-party hosting platforms to remove the podcast to address the US Food and Drug Administration's concerns.The company also said the television ad questioned by the regulator never aired.In addition, ImmunityBio said it is executing other measures to improve advertising compliance, including expanded promotional review protocols and mandatory executive training.In March, the FDA issued a warning letter to the company citing \"false or misleading\" promotional materials for Anktiva.Anktiva, or nogapendekin alfa inbakicept-pmln), is indicated in combination with Bacillus Calmette-Guerin for the treatment of adults with BCG-unresponsive nonmuscle invasive bladder cancer with carcinoma in situ with or without papillary tumors, the regulator said.Shares of ImmunityBio were up 1.2% pre-bell Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2625679011","isCrawlerRequest":true}